PierianDx

Saint Louis, United States Founded: 2014 • Age: 12 yrs Acquired By Velsera
Genetic tests for individualized disease diagnosis are provided.
Request Access

About PierianDx

PierianDx is a company based in Saint Louis (United States) founded in 2014 by Rakesh Nagarajan was acquired by Velsera in January 2023.. PierianDx has raised $69.35 million across 7 funding rounds from investors including Inova, RTI International and Orbimed. The company has 234 employees as of April 05, 2024. PierianDx has completed 1 acquisition, including Tute Genomics. PierianDx offers products and services including Clinical Genomics Workspace, Genomics Knowledgebase, Professional Services, and IVD Partnerships. PierianDx operates in a competitive market with competitors including ArcherDX, Personalis, Variantyx, ImaginAb and OncoDNA, among others.

  • Headquarter Saint Louis, United States
  • Employees 234 as on 05 Apr, 2024
  • Founders Rakesh Nagarajan
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Pieriandx India Private Limited
  • Date of Incorporation 07 Jan, 2016
  • Jurisdiction Pune City, Maharashtra, India
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $6.23 M (USD)
    50.92
    as on Mar 31, 2023
  • Net Profit
    $469.89 K (USD)
    60.43
    as on Mar 31, 2023
  • EBITDA
    $921.69 K (USD)
    57.12
    as on Mar 31, 2023
  • Total Equity Funding
    $69.35 M (USD)

    in 7 rounds

  • Latest Funding Round
    $30 M (USD), Series C

    Nov 02, 2021

  • Investors
    Inova

    & 8 more

  • Employee Count
    234

    as on Apr 05, 2024

  • Investments & Acquisitions
  • Acquired by
    Velsera

    (Jan 13, 2023)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of PierianDx

PierianDx offers a comprehensive portfolio of products and services, including Clinical Genomics Workspace, Genomics Knowledgebase, Professional Services, and IVD Partnerships. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Software for analyzing and interpreting genomic data in clinical settings.

Curated resource for accurate variant interpretations and treatment options.

Support for genomics workflows and assay validation processes.

Services for integrating genomic reporting in IVD assays.

People of PierianDx
Headcount 50-200
Employee Profiles 18
Employee Profiles
People
Manojkumar Patil
Project Manager
People
Abhishek Mandke
Associate Accountant
People
Jordan Thompson
Marketing Specialist
People
Snehal Patil
Senior Quality Assurance Engineer

Unlock access to complete

Funding Insights of PierianDx

PierianDx has successfully raised a total of $69.35M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $30 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 7
  • Last Round Series C — $30.0M
  • First Round
  • Investors Count 8
Date Amount Transaction Name Valuation Lead Investors Investors
Nov, 2021 Amount Series C - PierianDx Valuation Orbimed
Nov, 2021 Amount Debt – Conventional - PierianDx Valuation

investors

Oct, 2019 Amount Series B - PierianDx Valuation ATW Partners , SJF Ventures
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in PierianDx

PierianDx has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Inova, RTI International and Orbimed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
Founded Year Domain Location
Growth-stage US tech companies are funded by Health Catalyst Capital.
Founded Year Domain Location
ATW Partners is engaged in smart and strategic investing.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by PierianDx

PierianDx has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Tute Genomics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Cloud-based genome analysis for precision medicine is provided.
2012
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - PierianDx

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Pieriandx Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of PierianDx

PierianDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ArcherDX, Personalis, Variantyx, ImaginAb and OncoDNA, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Molecular cancer diagnostic products are developed using patented AMP technology.
domain founded_year HQ Location
Genomic sequencing and diagnosis software is provided for healthcare.
domain founded_year HQ Location
Genomics data analysis platform for healthcare diagnostics is offered.
domain founded_year HQ Location
ImaginAb is focused on developing advanced immuno-oncology imaging technologies.
domain founded_year HQ Location
Genomic and theranostic services for oncology precision medicine are delivered.
domain founded_year HQ Location
Provider of test panels for personalized cancer therapies
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Pieriandx

Frequently Asked Questions about PierianDx

When was PierianDx founded?

PierianDx was founded in 2014 and raised its 1st funding round 1 year after it was founded.

Where is PierianDx located?

PierianDx is headquartered in Saint Louis, United States. It is registered at Saint Louis, Missouri, United States.

Is PierianDx a funded company?

PierianDx is a funded company, having raised a total of $69.35M across 7 funding rounds to date. The company's 1st funding round was a Series B of $27M, raised on Jun 01, 2015.

How many employees does PierianDx have?

As of Apr 05, 2024, the latest employee count at PierianDx is 234.

What is the annual revenue of PierianDx?

Annual revenue of PierianDx is $6.23M as on Mar 31, 2023.

What does PierianDx do?

PierianDx was founded in 2014 in Saint Louis, United States, within the genetic testing sector. Patient-specific diagnoses and treatments for multiple diseases are delivered based on individual DNA analysis. Operations are supported by a proprietary cloud-based Clinical Genomicist Workstation software, which manages next-generation sequencing across six phases: case accessioning, sequencing, analysis, draft report, final report, and electronic health record integration.

Who are the top competitors of PierianDx?

PierianDx's top competitors include Personalis, ImaginAb and OncoDNA.

What products or services does PierianDx offer?

PierianDx offers Clinical Genomics Workspace, Genomics Knowledgebase, Professional Services, and IVD Partnerships.

How many acquisitions has PierianDx made?

PierianDx has made 1 acquisition, including Tute Genomics.

Who are PierianDx's investors?

PierianDx has 9 investors. Key investors include Inova, RTI International, Orbimed, ARUP Laboratories, and Velsera.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available